van den Bent, M.;
Brandes, A.;
Frenay, M.;
Fumoleau, P.;
Stupp, R.;
Dittrich, C.;
Coudert, B.;
Clement, P.;
Lacombe, D.;
Raymond, E.
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study
Beteiligte:
van den Bent, M.;
Brandes, A.;
Frenay, M.;
Fumoleau, P.;
Stupp, R.;
Dittrich, C.;
Coudert, B.;
Clement, P.;
Lacombe, D.;
Raymond, E.
Erschienen:
American Society of Clinical Oncology (ASCO), 2005